Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Shareholder Meeting (November 2022)
21 slides from Proteomics International Laboratories's shareholder meeting presentation, Nov 24, 2022
Slide 1: AGM Chairman's Address and Investor Presentation (ASX Release)
ASX Release 24 November 2022 ASX code: PIQ AGM Chairman’s Address and Investor Presentation Proteomics International Laboratories Ltd (Proteomics International; ASX: PIQ) is pleased to release a copy of the Chairman’s Address to be provided by Mr Neville Gardiner and the Investor Presentation to be
Slide 2: Chairman's Address
Chairman’s Address My name is Neville Gardiner, and as Chair of the company it is my pleasure to welcome you to the 8th Annual General Meeting of shareholders of Proteomics International Laboratories. It is now after 9:30 am, and as we have a quorum of shareholders present, I declare the meeting ope
Slide 3: Proteomics International AGM Presentation
ASX: PIQ Proteomics International LABORATORIES LTD AGM Presentation 2022 – an inflection point 24 November 2022 Dr. Richard Lipscombe Managing Director
Slide 4: Disclaimer
Disclaimer ASX: PIQ ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (Proteomics International, Proteomics, the Company, ASX: PIQ). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associ
Slide 5: Proteomics International Laboratories Ltd
Proteomics International Laboratories Ltd ASX: PIQ ASX:PIQ A medical technology company at the forefront of Corporate Snapshot – 21/11/2022 precision medicine and predictive diagnostics ASX code PIQ Share Price A$0.91 Diagnostics (Dx) Shares on issue (+7.6m options) 115m PromarkerD Market Capitalisa
Slide 6: Board of Directors
Board of Directors ASX: PIQ Neville Gardiner BBus (Accounting and Business Law) (Curtin), CA, MAICD, Non-Executive Chair ASX:PIQ Seasoned finance professional with over 30 years’ experience providing South & corporate advice to Boards of public and private companies. Neville was Co-Founder and MD of
Slide 7: Promarker – Platform Technology
Promarker – Platform Technology ASX: PIQ ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics International to create novel diagnostic tests 5
Slide 8: Promarker D
Promarker D PROACTIVELY CHANGING RENAL HEALTHCARE A simple blood test for predicting diabetic kidney disease
Slide 9: Problem & Solution
Problem & Solution ASX: PIQ ASX:PIQ Current standard-of-care diagnostics • Existing tests (known as eGFR and ACR) can only detect chronic kidney disease once it is already present • Current standard-of-care tests cannot predict the Roadblock onset of diabetic kidney disease The Problem • If unchecke
Slide 10: PromarkerD is Revenue Ready
PromarkerD is Revenue Ready ASX: PIQ The PromarkerD predictive test is rolling out in key markets ASX:PIQ Enormous Market ✓ 537m adults have diabetes globally: 1-in-3 currently have diabetic kidney disease (DKD) Peer reviewed publications – Clinical & analytical validity proven (Sensitivity 86%); Hi
Slide 11: PromarkerD – Simple Integration & Utilisation
PromarkerD – Simple Integration & Utilisation ASX: PIQ ASX:PIQ Blood sample drawn Biomarkers analysed Results analysed by Results and intervention PromarkerD Hub software plan delivered Sample is drawn at clinic Laboratory uses a standard Cloud based algorithm, the Clinician delivers results or path
Slide 12: PromarkerD – Results & Intervention
PromarkerD – Results & Intervention How PromarkerDTM results are delivered LOW RISK MODERATE RISK HIGH RISK RISK SCORE % 0 10 20 100 Prognostic 16% indicates a moderate risk of decline in kidney function* Risk Score Intervention Testing Regimen Low Risk • Standard diabetes management Test Annually •
Slide 13: PromarkerD in the Clinic
PromarkerD in the Clinic ASX: PIQ PromarkerD significantly enhances diabetic kidney disease diagnosis and management ASX:PIQ Peer reviewed PromarkerD tested on over 5,000 patients in 4-year clinical studies PromarkerD predicted 86% of otherwise healthy diabetics who went on to develop chronic kidney
Slide 14: PromarkerD Market Opportunity
PromarkerD Market Opportunity ASX: PIQ ASX:PIQ 45% Diabetes incidence and Patent portfolio undiagnosed Country Patent/Application No Patent Status No. Diabetics1 Australia 2011305050 Granted 1,491,800 Brazil BR112013006740 Granted 15,733,600 537M Canada 2811654 Granted 2,974,000 China ZL201180053583
Slide 15: PromarkerD – Route to US and Global Markets
PromarkerD – Route to US and Global Markets ASX: PIQ Key Markets ASX:PIQ United States • Binding Letter of Intent signed with Sonic Healthcare USA Diagnostic laboratory • LOI details terms and conditions to market and sell licenses PromarkerDTM PromarkerD in the USA • PromarkerD test now available o
Slide 16: Diagnostics Pipeline
Diagnostics Pipeline ASX: PIQ ASX:PIQ Further Global Potential in New Markets ▪ Employs the Promarker™️ technology platform to develop novel intellectual property The Promarker™️ Research ▪ Targeting new diagnostic tests in areas of significant unmet need Pipeline & Timeline ▪ Enormous markets and r
Slide 17: In Development: Endometriosis
In Development: Endometriosis ▪ Endometriosis is a common and painful disease where tissue that normally lines the uterus grows into other organs ▪ Currently diagnosis takes an average of 7.5 years and requires invasive surgery (laparoscopy) ▪ Affects 1 in 9 women and costs Australia over AU$10 bill
Slide 18: Timeline & Milestones
Timeline & Milestones ASX: PIQ ASX:PIQ 2022 Achievements 2023 Targets & Milestones 29 Aug 2022 1 Aug 2022 OxiDx P/L spin-out Potential breakthrough launched for Finalisation of 16 Jun 2022 blood test able to detect oxidative stress Sonic Healthcare Completion of 7 Feb 2022 Manufacturing people with
Slide 19: Value Inflection Points
Value Inflection Points ASX: PIQ ASX:PIQ Exceptional Global Share Price Catalysts FY23 Opportunity Milestone Dec Qtr ’22 1H CY23 Impact ➢ Disruptive, cutting-edge technology & PromarkerD proven in-house diagnostics platform Execution of Sonic Healthcare USA licence; Licensing Deals ➢ PromarkerD test
Slide 20: Peer Comparison
Peer Comparison ASX: PIQ ASX:PIQ Market Share FY22 FY22 Net Stock Code Company Focus Capitalisation Price Revenue Profit/Loss Predictive blood test measuring novel protein Proteomics biomarkers for DKD; simple, cost effective, International PIQ.ASX commercial ready. A$105m A$0.91 A$1.7m A$4.9m loss
Slide 21: Contact
Contact ASX: PIQ ASX:PIQ Dr Richard Lipscombe Kyle Moss Managing Director Corporate Advisor T:+61 8 9389 1992 Euroz Hartleys E: enquiries@proteomicsinternational.com T:+61 9488 1400 www.proteomicsinternational.com E: kmoss@eurozhartleys.com Dirk van Dissel Investor Relations & Corporate Advisor Cand
Proteomics International Laboratories — Shareholder Meeting (November 2022) on 6ix